Researchers have recently sought out pharmacologic means of increasing rates of urinary stone passage. We outline the current understanding in medical expulsive therapy.
Introduction
In the absence of infection, severe obstruction and acute severe colic, a trial of conservative therapy is warranted for the majority of ureteral stones. Studies have shown spontaneous passage rates of 71-98% for small (below 5 mm) distal ureteral stones [1,2] with stone size and location being the two most important predictors of stone passage [3] . Alternatively, minimally invasive therapies such as extracorporeal shock wave lithotripsy (SWL), ureteroscopy and percutaneous nephrostolithotomy have emerged, altering surgical treatment dramatically for urolithiasis. Although efficacious, these techniques are not without morbidity and are quite costly [1, 4] .
In light of these data, researchers have recently sought out pharmacologic means of increasing rates of stone passage and reducing surgical intervention. The use of hormones, nonsteroidal anti-inflammatories, calcium channel blockers, corticosteroids and adrenergic a antagonists have all been proposed as a way to enhance stone passage. Hormones including prostaglandins and glucagon remain of historical interest only at this time [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . While nonselective cyclooxygenase inhibitors have efficacy in urinary colic, studies examining their use in medical expulsion therapy have been limited and inconclusive. Multiple randomized clinical trials involving calcium channel blockers and adrenergic a agonists have demonstrated these drugs to be clinically efficacious, safe and well tolerated. Here, we will review the recent clinical data and present clinical recommendations.
Calcium channel blockers
The primary anatomic unit of the ureter is the smooth muscle cell, which functions in response to changes in calcium ion concentration. An increase in calcium concentration causes contraction. Conversely, a decrease in calcium concentration results in relaxation. Ureteral stones induce ureteral spasm and this is thought to arrest stone passage [16] . Blocking calcium action on cells has been proposed to decrease ureteral contractions and subsequently decrease the pain of ureteral colic.
Six studies evaluating nifedipine as medical expulsive therapy have been reported to date (Table 1) [16] [17] [18] [19] [20] [21] . All studies have demonstrated a favorable benefit to nifedipine in facilitating stone passage with only one study failing to reach statistical significance. Today, adrenergic a antagonists have become commonplace over calcium channel blockers for medical expulsive therapy.
Adrenergic a antagonists
Studies have demonstrated that both a and b adrenergic receptors are located in the human ureter, although the a receptors predominate [22] . These a receptors are further subclassified into a 1 and a 2 receptors. In turn, a 1 receptors are further classified into subtypes based on their differential selectivity: a 1a (proximal urethra, prostate, bladder outlet), a 1b (vessel smooth muscle) and a 1d (detrusor, lower ureter). Of the known a 1 receptor subtypes, a 1d receptors have the most pronounced effect on detrusor contraction and spasm of the lower ureter, particularly the intramural portion [23] . These receptors appear to be ideal targets for pharmacotherapy as they represent the greatest impediment to stone passage.
The a receptor antagonists have long been used to treat symptoms of benign prostatic hypertrophy and prostatitis. Their mechanism is via smooth muscle relaxation of the prostate and bladder neck via inhibition of a 1a receptors, resulting in increased urinary flow. Tamsulosin is uroselective for the a 1a and a 1d receptors resulting in an overall lower side effect profile compared to the nonselective agents. In the ureter, a 1 adrenergic receptor antagonists inhibit basal tone, and also decrease peristaltic frequency and amplitude. Consequently, intraureteral pressure decreases and fluid transport increases. Given its receptor specificity and in-vitro findings, it seems plausible that tamsulosin would be useful in the treatment of obstructive ureteral calculi.
Several recent clinical trials have shown that a 1 blockers are not only useful for stone expulsion, but for control of stone colic as well (Table 2) [18,21-23,24 -26 ] . In a groundbreaking study, Porpiglia et al. [24 ] sought out to determine if the treatment success of tamsulosin and corticosteroids was a result of a single drug or association of the two. In total, 114 patients with distal ureteral stones greater than 5 mm were enrolled into four groups. The first group received tamsulosin 0.4 mg daily, the second group received deflazacort 30 mg daily, the third group received both medications and the fourth group received only analgesics. Treatment duration was 10 days to limit the side effects of prolonged corticosteroid therapy. The rates of expulsion for the four groups were 60, 37.5, 84.8 and 33.3%, respectively. There was a statistical difference between the combined tamsulosin and deflazacort group and the other groups. Only two cases of drug side effects were reported with no drop outs. The authors conclude that the use of corticosteroids is efficient only when administered together with a 1 blockers (tamsulosin). In addition, tamsulosin used on its own as a medical expulsive therapy can be considered as an alternative treatment for those patients who are not suitable for steroid therapy [24 ] .
De Sio [25 ] recently published a series of 96 patients with distal ureteral stones. Forty-six patients were randomized to receive diclofenac 100 mg daily plus aescin 80 mg daily. Fifty patients received the same treatment plus tamsulosin 0.4 mg daily (maximum 2 weeks). Aescin, a saponin derived from the horse chestnut tree, inhibits edema formation by decreasing vascular fragility. The tamsulosin group achieved statistically significantly higher rates Medical expulsive therapy Sterrett and Nakada 211 Hollingsworth et al. [27 ] published further validation of medical expulsive therapy with a meta-analysis assessing the efficacy of drug therapy in facilitating spontaneous passage of ureteral stones. Their study shows a benefit for calcium channel blockers and a adrenergic antagonists. They also concluded that the addition of corticosteroids might have a small advantage, but the benefit of drug therapy is not lost in those patients in whom corticosteroids might be contraindicated.
The administration of a adrenergic blockers may also be considered as an adjunct for SWL. In a prospective, randomized, double-blind, placebo controlled study, Bhagat et al. [28 ] evaluated 60 patients with a solitary renal or ureteral calculus undergoing SWL. The study group (30) received 0.4 mg tamsulosin and the control group (30) received placebo daily until stone clearance or for a maximum of 30 days. The tamsulosin group was found to have significantly higher clearance rates (96.6%) compared to the placebo group (79.3%). Average analgesic use and rates of steinstrasse were also lower in the tamsulosin group, although not statistically significant.
Conclusion
Medical expulsive therapy should be considered for all patients with ureteral stones who are candidates for observation. High levels of clinical and laboratory evidence have shown that medical expulsive therapy improves stone passage rates, decreases stone expulsion times, and reduces the need for analgesic therapy, hospitalization, and surgery in appropriately selected individuals. Specifically, tamsulosin appears to be most effi-cacious when used in combination with a corticosteroid, but is also effective if used as single drug therapy. The nonselective adrenergic a blockers also appear to be effective as well. Increased understanding of ureteral physiology will allow for future development of medical expulsive therapies.
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